Oppenheimer Downgrades Ventyx Biosciences to Perform After Eli Lilly's $14 Acquisition
Oppenheimer analyst Jeff Jones downgraded Ventyx Biosciences to Perform from Outperform without a price target after after Eli Lilly entered an agreement to acquire all outstanding shares of Ventyx for $14 in cash.
